Seroquel Patent Expiration Leads To Sharp 2Q Revenue Decline For AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
With U.S. revenues down 29% and the EU take off by 20%, perhaps AstraZeneca’s greatest concern is only 1% revenue growth in emerging markets, which the pharma has targeted as a key revenue-driver through its patent cliff.